Smallish part of their overall revenue stream. Good news of course but not nearly enough to make them undervalued. PFE got the jump and might sell twice as many doses as JNJ for year one. PFE projects maybe 15% of their total revenue for, VAX and JNJ is higher sales base. I really thought it would be worth a few bucks in higher PFE share price. Nope, every bit of gains were retraced. I am just guessing they start over with next years version as this thing mutates and some will need vaccinated at least another year or two. It's going to feed cashflow, just not likely to drive a major Pharma higher. To my knowledge they all agreed to not price gouge, and the GOV paid for a lot of doses even prior to approval to make it worth the accelerated effort if it was a fail. The single dose shot from JNJ is good, but the reality is the world will buy everything any company can manufacture for many months to come.
And my three year old AAPL comments above sound trivial today.
And my three year old AAPL comments above sound trivial today.